SCHEMBL5356965

SCHEMBL5356965

CCC(=O)c1cccc(N2CCCCC2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.64
HPGD P15428 5/20 0.64
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
HSD17B10 Q99714 2/20 0.64
KDM4E B2RXH2 2/20 0.64
GAA P10253 1/20 0.64
MAPT P10636 6/20 0.57
TSHR P16473 3/20 0.57
PLOD2 O00469 3/20 0.51
PLOD3 O60568 3/20 0.51
PLOD1 Q02809 3/20 0.51
HTT P42858 1/20 0.50
GLA P06280 1/20 0.48
KMO O15229 1/20 0.48
PRMT6 Q96LA8 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
L3MBTL3 Q96JM7 1/20 0.47
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10691285 0.98 ALDH1A1 (0.62) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL10755573 0.98 ALDH1A1 (0.66) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL7351790 0.85 PLOD2 (0.52) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL3831932 0.85 KMO (0.68) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL9081605 0.84 ALDH1A1 (0.64) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL341384 0.83 ALDH1A1 (0.66) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL32688300 0.82 ALDH1A1 (0.54) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL8349198 0.82 ALDH1A1 (0.70) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL17928976 0.81 ALDH1A1 (0.46) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL10144997 0.81 ALOX5 (0.60) ALDH1A1HPGDMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307091-B2 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds BDD BEROLINA DRUG DEVELOPMENT GMBH (DE) 2007-12-11 US claimed
CN-101002770-A Deuterated 3-piperidinophenylethyl ketones and pharmaceutical compositions containing them BDD BEROLINA DRUG DEV GMBH (DE) 2007-07-25 CN claimed
CN-1293064-C Deuterated 3-piperidinopropiophenone and pharmaceutical compositions containing same TOURIKOUM DRUG DEV AB (DE) 2007-01-03 CN claimed
EP-1383752-B1 DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SAID COMPOUNDS TURICUM DRUG DEV AG (CH) 2005-06-22 EP claimed
US-20040186136-A1 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds BDD BEROLINA DRUG DEVELOPMENT GMBH (DE) 2004-09-23 US claimed
CN-1527823-A Deuterated 3-piperidinopropiophenone and pharmaceutical compositions containing same ͼ���ķҩ�x{FDE2}չ�ɷݹ�˾ 2004-09-08 CN claimed
EP-1383752-A2 DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SAID COMPOUNDS Turicum Drug Development AG (CH) 2004-01-28 EP claimed
WO-2002088100-A2 DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SAID COMPOUNDS TURICUM DRUG DEVELOPMENT AG (CH) 2002-11-07 WO claimed
CN-105164125-A 2-phenyl or 2-heteroaryl imidazo [1, 2-a ] pyridine derivatives HOFFMANN LA ROCHE 2015-12-16 CN disclosed
CN-101311171-B Compound with dual restraining activities to acetyl cholinesterase and butyryl cholinesterase and use thereof INST MATERIA MEDICA CAMS 2011-09-28 CN disclosed
CN-101311171-A Compound with dual restraining activities to acetyl cholinesterase and butyryl cholinesterase and use thereof INST MATERIA MEDICA CAMS (CN) 2008-11-26 CN disclosed
US-7307091-B2 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds BDD BEROLINA DRUG DEVELOPMENT GMBH (DE) 2007-12-11 US disclosed
US-7307091-B2 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds BDD BEROLINA DRUG DEVELOPMENT GMBH (DE) 2007-12-11 US disclosed
US-7307091-B2 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds BDD BEROLINA DRUG DEVELOPMENT GMBH (DE) 2007-12-11 US disclosed
CN-1527823-A Deuterated 3-piperidinopropiophenone and pharmaceutical compositions containing same ͼ���ķҩ�x{FDE2}չ�ɷݹ�˾ 2004-09-08 CN disclosed
EP-1383752-A2 DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SAID COMPOUNDS Turicum Drug Development AG (CH) 2004-01-28 EP disclosed
EP-1383752-A2 DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SAID COMPOUNDS Turicum Drug Development AG (CH) 2004-01-28 EP disclosed
WO-2002088100-A3 DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SAID COMPOUNDS BEROLINA DRUG DEV AB (SE) 2003-05-30 WO disclosed
WO-2002088100-A2 DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SAID COMPOUNDS TURICUM DRUG DEVELOPMENT AG (CH) 2002-11-07 WO disclosed
WO-2002088100-A2 DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SAID COMPOUNDS TURICUM DRUG DEVELOPMENT AG (CH) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186136-A1 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds MUSK, CPT1B, PYGM ALDH1A1 1601/4885HPGD 223/4885MEN1 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.